In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Hims & Hers Health Inc (NYSE: HIMS) was $55.52 for the day, down -12.36% from the previous closing price of $63.35. In other words, the price has decreased by -$12.36 from its previous closing price. On the day, 105.5 million shares were traded. HIMS stock price reached its highest trading level at $64.11 during the session, while it also had its lowest trading level at $54.71.
Ratios:
Our analysis of HIMS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 106.70. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65.
TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 31 ’25 when Chi Michael sold 26,350 shares for $67.00 per share. The transaction valued at 1,765,450 led to the insider holds 278,654 shares of the business.
Chi Michael sold 250 shares of HIMS for $16,110 on Aug 01 ’25. The Chief Commercial Officer now owns 278,654 shares after completing the transaction at $64.44 per share. On Aug 01 ’25, another insider, Chi Michael, who serves as the Officer of the company, bought 250 shares for $64.44 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 12548630528 and an Enterprise Value of 12433915904. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 69.49, and their Forward P/E ratio for the next fiscal year is 62.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.17 while its Price-to-Book (P/B) ratio in mrq is 22.28. Its current Enterprise Value per Revenue stands at 6.175 whereas that against EBITDA is 78.266.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.17, which has changed by 2.4613466 over the last 52 weeks, in comparison to a change of 0.21149921 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $13.47. The 50-Day Moving Average of the stock is 3.17%, while the 200-Day Moving Average is calculated to be 43.20%.
Shares Statistics:
HIMS traded an average of 45.89M shares per day over the past three months and 47649890 shares per day over the past ten days. A total of 217.38M shares are outstanding, with a floating share count of 199.84M. Insiders hold about 10.72% of the company’s shares, while institutions hold 70.10% stake in the company. Shares short for HIMS as of 1752537600 were 65295727 with a Short Ratio of 1.42, compared to 1749772800 on 61690896. Therefore, it implies a Short% of Shares Outstanding of 65295727 and a Short% of Float of 36.230000000000004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Hims & Hers Health Inc (HIMS) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.26, with high estimates of $0.31 and low estimates of $0.17.
Analysts are recommending an EPS of between $1.24 and $0.78 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.38, with 5.0 analysts recommending between $1.77 and $0.99.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 10 analysts are estimating revenue of $635.17M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $615.54M.
A total of 12 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.31B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 11 analysts’ estimates, the company’s revenue will be $2.82B in the next fiscal year. The high estimate is $3B and the low estimate is $2.66B.
